Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTA Trial
NCT07157631Recruiting
- Sponsor
- Renji Hospital
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of tranexamic acid in liver disease (2 arms), sponsored by Renji Hospital. Primary endpoints: Primary efficacy outcome: Blood loss at 24 hours and Primary safety outcome: Composite of thrombotic events at 7 days. Started Nov 2025; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
liver disease
Beyond the preview
Go deeper on NCT07157631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07157631.